Growth Prospects in the Short Bowel Syndrome Market 2030
Added: (Thu May 11 2023)
Pressbox (Press Release) -
Market Overview
A collection of issues associated with inadequate nutrition absorption is known as short bowel syndrome. Depending on how effectively the small intestine is working, it might be mild, moderate, or severe. The surgical removal of a section of the small intestine is the primary cause of short bowel syndrome. This procedure can cure birth abnormalities, traumas, and digestive illnesses.
Market Size Growth Rate:
The SBS market was estimated at USD 1.24 billion in 2021 and is anticipated to grow at a CAGR of 15.9% from 2022 to 2027, reaching USD 4.42 billion. The global market for short bowel syndrome is expected to grow as a result of intensive research and development, novel medications, thorough study, the prevalence of the condition, and a good reimbursement environment.
Market Drivers:
The GLP-2 is projected to be one of the SBS market's top categories during future expansion. Gattex/Revestive is the sole GLP-2 analogue for the treatment of SBS that is marketed today. The high cost of the medication, the rise in the number of patients receiving gattex therapy, and the increase in prescriptions for the treatment may all be blamed for the segment's rapid expansion.
Market Opportunities:
The majority of bleeding disorder treatment market participants are actively striving to create new pharmacological products and therapy techniques to expand the range of available bleeding treatment alternatives.
• Glepaglutide, a long-acting GLP-2 analogue under investigation in Phase 3 clinical trials for the treatment of SBS, was granted Orphan Drug Designation by the FDA in October 2022 to Zealand Pharma.
• The Duke Clinical Research Institute (DCRI) and 9 Meters Biopharma collaborated to promote the clinical development of 9 Meters' candidate NM-002, a long-acting GLP-1 agonist that is now in Phase 2 development for SBS, in April 2021.
• In June 2021, VectivBio Holding AG got FDA clearance for Orphan medication designation to Apraglutide, a next-generation, long-acting GLP-2 analogue in uncommon gastrointestinal (GI) illnesses, and VectivBio AG expects to launch a phase 2 study testing Apraglutide for the treatment of a GVHD in 2022.
Recent Developments in the Industry:
• In April 2021, Hanmi Pharm. Co. Ltd. received approval from U.S.FDA for LAPS GLP-2 analogue (HM15912) a new biopharmaceutical product in SBS therapy
• On April 2020, 9 Meters Biopharma, Inc. completed the merger with RDD Pharma, Ltd., an Israel-based corporation (RDD), and changed its name from Innovate Biopharmaceuticals, Inc. to 9 Meters Biopharma, Inc.
• In February 2020 Scottish Medicines Consortium revealed NHS Scotland approval for Revestive (teduglutide) in adult patients with SBS.
Market Segmentation:
As per the research analysis, the global short bowel syndrome market is segmented by product into Glucagon-like Peptide-2 (GLP2), growth hormone, glutamine, and others by distribution channel into hospital pharmacies, retail pharmacies, and online sales
On the bases of the product, the GLP2 segment is a 33 amino acid peptide-encoded carboxyterminal to the sequence of GLP-1 in the proglucagon gene. Both GLP-1 and GLP-2 are secreted from gut endocrine cells and promote nutrient absorption through distinct mechanisms of action. It plays significant functions such as GLP-2 reduces mortality and decreases mucosal injury, cytokine expression, and bacterial septicemia in the setting of small and large bowel inflammation, and also enhances nutrient absorption and gut adaptation in humans with short bowel syndrome.
Geographical Classification:
The global short bowel syndrome market is segmented into major countries including North America, Europe, South America, Asia Pacific, and the Middle East and Africa.
Competitive Analysis:
However, it is expected to grow rapidly in the next couple of years with intense competition among the players and a rising number of cases. A few key players are already being observed adopting strategies, such as collaboration for the development of therapies and drugs, which may make the market crowded with new products in the next couple of years.
Major Companies:
Takeda Pharmaceutical Company Limited (Japan), VectivBio AG, 9 Meters Biopharma, Zealand Pharma (Denmark), Hikma Pharmaceuticals (U.K.), Johnsons & Johnsons Services Inc (U.S.), Boehringer Ingelheim International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Sanofi (France), GSK Plc. (U.K.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.), Alvogen (U.S), Merck KGaA (Germany), Swedish Orphan Biovitrum (Switzerland), OxThera, Mylan (US), AstraZeneca (UK), and Others.
Download free sample: https://www.pharmanucleus.com/reports/short-bowel-syndrome-market-is-expected-to-grow-at-exponential-pace-during-forecast-period-of-2022-2027
Contact Us:
John.M
john.m@pharmanucleus.com
Support: +44 (0)20 8470 4967
https://www.pharmanucleus.com/